Literature DB >> 18490915

B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.

E Fronkova1, K Muzikova, E Mejstrikova, M Kovac, R Formankova, P Sedlacek, O Hrusak, J Stary, J Trka.   

Abstract

Minimal residual disease (MRD) detection using quantification of clone-specific Ig or TCR rearrangements before and after transplantation in children with high-risk ALL is an important predictor of outcome. The method and guidelines for its interpretation are very precise to avoid both false-negative and -positive results. In a group of 21 patients following transplantation, we observed detectable MRD positivities in Ig/TCR-based real-time quantitative PCR (RQ-PCR) leading to no further progression of the disease (11 of 100 (11%) total samples). We hypothesized that these positivities were mostly the result of nonspecific amplification despite the application of strict internationally agreed-upon measures. We applied two non-self-specific Ig heavy chain assays and received a similar number of positivities (20 and 15%). Nonspecific products amplified in these RQ-PCR systems differed from specific products in length and sequence. Statistical analysis proved that there was an excellent correlation of this phenomenon with B-cell regeneration in BM as measured by flow cytometry and Ig light chain-kappa excision circle quantification. We conclude that although Ig/TCR quantification is a reliable method for post transplant MRD detection, isolated positivities in Ig-based RQ-PCR systems at the time of intense B-cell regeneration must be viewed with caution to avoid the wrong indication of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490915     DOI: 10.1038/bmt.2008.122

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

1.  Increased immature T-cells detected by flow cytometry in post chemotherapeutic patients with acute myeloid leukemia, a case report and small series study.

Authors:  Xiuxu Chen; Stephen Albrecht; Wei Cui; Da Zhang
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Thymic and bone marrow output in patients with common variable immunodeficiency.

Authors:  Federico Serana; Paolo Airò; Marco Chiarini; Cinzia Zanotti; Mirko Scarsi; Micol Frassi; Vassilios Lougaris; Alessandro Plebani; Luigi Caimi; Luisa Imberti
Journal:  J Clin Immunol       Date:  2011-04-14       Impact factor: 8.317

Review 3.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  Simultaneous quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) by real-time PCR.

Authors:  Alessandra Sottini; Federico Serana; Diego Bertoli; Marco Chiarini; Monica Valotti; Marion Vaglio Tessitore; Luisa Imberti
Journal:  J Vis Exp       Date:  2014-12-06       Impact factor: 1.355

5.  Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Authors:  A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

Review 6.  [Clinical application of minimal residual disease detection in childhood acute leukemia].

Authors:  Yan-Qin Cheng; Xiao-Wen Zhai
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

Review 7.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Blood Adv       Date:  2017-11-28

Review 8.  Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.

Authors:  Renato Bassan; Orietta Spinelli
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

9.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Authors:  M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

10.  Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patients.

Authors:  Marina Motta; Marco Chiarini; Claudia Ghidini; Cinzia Zanotti; Cinzia Lamorgese; Luigi Caimi; Giuseppe Rossi; Luisa Imberti
Journal:  J Transl Med       Date:  2010-11-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.